Cargando…

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer

In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbas, Mahmoud, Heitplatz, Barbara, Bernemann, Christof, Boegemann, Martin, Trautmann, Marcel, Schrader, Andres Jan, Wardelmann, Eva, Schlack, Katrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644361/ https://www.ncbi.nlm.nih.gov/pubmed/38020299 http://dx.doi.org/10.3892/ol.2023.14114

Ejemplares similares

Trop-2 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2022)

Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?
por: Klaile, Yvonne, et al.
Publicado: (2016)

TACSTD2 upregulation is an early reaction to lung infection
por: Lenárt, Sára, et al.
Publicado: (2022)

The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study
por: Farag, Azza Gaber Antar, et al.
Publicado: (2021)

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
por: Poteska, Renata, et al.
Publicado: (2022)

Novel TACSTD2 mutation in gelatinous drop-like corneal dystrophy
por: Jongkhajornpong, Passara, et al.
Publicado: (2015)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

Immunohistochemical Expression of HBME-1 and TROP-2 in Some Follicular-Derived Thyroid Lesions
por: Abu-Seadah, Shimaa Shafik, et al.
Publicado: (2023)

Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer
por: Kushiyama, Shuhei, et al.
Publicado: (2021)

The role of tacstd-2 level in hepatitis C patients (controlled clinical research)
por: Sahin, Memduh, et al.
Publicado: (2019)

Expression of Spred2 in the urothelial tumorigenesis of the urinary bladder
por: Oda, Shinsuke, et al.
Publicado: (2021)

Comprehensive Gene Expression Analyses of Immunohistochemically Defined Subgroups of Muscle-Invasive Urinary Bladder Urothelial Carcinoma
por: Kim, Bohyun, et al.
Publicado: (2021)

ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis
por: Schlack, Katrin, et al.
Publicado: (2021)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis
por: Sayama, Yusuke, et al.
Publicado: (2021)

Identification and characterization of a novel TACSTD2 mutation in gelatinous drop-like corneal dystrophy
por: Paliwal, Preeti, et al.
Publicado: (2010)

Novel Mutations in TACSTD2 Gene in Families with Gelatinous Drop-like Corneal Dystrophy (GDLD)
por: Alehabib, Elham, et al.
Publicado: (2017)

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting
por: Boegemann, Martin, et al.
Publicado: (2019)

Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study
por: Elwy, Amira Emad, et al.
Publicado: (2019)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate
por: Boegemann, Martin, et al.
Publicado: (2016)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
por: Aydin, Ahmet Murat, et al.
Publicado: (2017)

Nested variant of urothelial carcinoma of the urinary bladder
por: Terada, Tadashi
Publicado: (2011)

Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants
por: Fan, Yu, et al.
Publicado: (2022)

Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving (177)Lu-PSMA-617 Radioligand Therapy
por: Kessel, Katharina, et al.
Publicado: (2020)

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
por: Boegemann, Martin, et al.
Publicado: (2017)

DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers
por: Katzendorn, Olga, et al.
Publicado: (2021)

Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder
por: Moradi Tabriz, Hedieh, et al.
Publicado: (2021)

Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells
por: Zhang, Lianhua, et al.
Publicado: (2018)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Postnatal Growth and DNA Methylation Are Associated With Differential Gene Expression of the TACSTD2 Gene and Childhood Fat Mass
por: Groom, Alexandra, et al.
Publicado: (2012)

A novel TACSTD2 mutation identified in two Chinese brothers with gelatinous drop-like corneal dystrophy
por: Jing, Yang, et al.
Publicado: (2009)

Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis
por: Wang, F, et al.
Publicado: (2014)

Diagnostic algorithm for papillary urothelial tumors in the urinary bladder
por: Shim, Jung-Weon, et al.
Publicado: (2008)

Review: Application of Nanoparticles in Urothelial Cancer of the Urinary Bladder
por: Chen, Chieh-Hsiao, et al.
Publicado: (2015)

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody
por: Raji, Rhoda, et al.
Publicado: (2011)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Clinical and Ultrastructural Studies of Gelatinous Drop-Like Corneal Dystrophy (GDLD) of a Patient with TACSTD2 Gene Mutation
por: Masmali, Ali, et al.
Publicado: (2019)

HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
por: Kim, Bohyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ab515kddd0qdpj7h803v1lobme